• 58914 Citations
1976 …2023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Training Experience

1982Internship, University of Chicago Hospitals
1985Residency, University of Chicago Hospitals
1986Residency, University of Wisconsin Hospital & Clinics
1989Fellowship, University of Wisconsin Hospital & Clinics

Education/Academic qualification

MD, Albert Einstein College

… → 1981


  • Genomic Medicine/Personalized Medicine
  • Immunology
  • Kidney Cancer / Urinary Tract Cancer
  • Skin Cancer

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Melanoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2011 2023

Allergy and Immunology

Research Output 1976 2019

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G., Ma, R., Li, H., Zhang, Y., Fang, D., Sosman, J. A. & Zhang, B., Dec 1 2019, In : Nature communications. 10, 1, 150.

Research output: Contribution to journalArticle


Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journalArticle


Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients with Metastatic Melanoma

Davis, E. J., Perez, M. C., Ayoubi, N., Zhao, S., Ye, F., Wang, D. Y., Sosman, J. A., Al-Rohil, R. N., Eroglu, Z. & Johnson, D. B., Jul 1 2019, In : Journal of Immunotherapy. 42, 6, p. 221-227 7 p.

Research output: Contribution to journalArticle

Neoplasm Metastasis
Disease-Free Survival
1 Citation (Scopus)

Genomic features of exceptional response in vemurafenib cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma

Yan, Y., Wongchenko, M. J., Robert, C., Larkin, J., Ascierto, P. A., Dreno, B., Maio, M., Garbe, C., Chapman, P. B., Sosman, J. A., Shi, Z., Koeppen, H., Hsu, J. J., Chang, I., Caro, I., Rooney, I., McArthur, G. A. & Ribas, A., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3239-3246 8 p.

Research output: Contribution to journalArticle

RNA Sequence Analysis